Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
Contineum Therapeutics reported its third-quarter 2026 financial results.
Story updates
09:06:09 PM UTC
SquawkNews
Contineum Therapeutics reported third-quarter 2026 results and said its projected cash runway extends through mid-2029. The release did not provide financial figures or a prior-period comparison.Material DetailsContext by AI AnalystThis is a mid-cycle update for a clinical-stage company, with PIPE…
09:13:40 PM UTC
SquawkNews
Contineum Therapeutics reported a net loss of $18.7 million for the third quarter of 2026, compared with $12.8 million a year earlier. Research and development expenses rose 45% to $16.0 million, while cash, cash equivalents and marketable securities totaled $244.5 million at quarter-end. The compa…
09:22:46 PM UTC
SquawkNews
Contineum Therapeutics reported a net loss of $18.7 million for the third quarter of 2026, compared with a $12.8 million loss a year earlier. Loss per share was $0.49, versus $0.45 in the prior-year quarter.Financial HighlightsBusiness HighlightsOriginal SEC Filing: Contineum Therapeutics, Inc. [ C…
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its third-quarter 2026 financial results.“Lysophosp…